|NYSE: BME||Financial Services / Asset Management / USA|
|41.86||+0.4800||+1.16%||Vol 38.04K||1Y Perf -9.09%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 69.40|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★★★★+ 56.93|
|Price Range Ratio 52W %||40.94||Earnings Rating||—|
|Market Cap||580.18M||Earnings Date||-|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|-62 046 100.00|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||29.44K|
|Avg. Monthly Volume||32.97K|
|Avg. Quarterly Volume||27.69K|
Blackrock Health Sciences Trust (NYSE: BME) stock closed at 41.86 per share at the end of the most recent trading day (a 1.16% change compared to the prior day closing price) with a volume of 38.04K shares and market capitalization of 580.18M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Asset Management industry, Financial Services sector and employs 0 people. Blackrock Health Sciences Trust CEO is John M. Perlowski.
The one-year performance of Blackrock Health Sciences Trust stock is -9.09%, while year-to-date (YTD) performance is -3.95%. BME stock has a five-year performance of 19.6%. Its 52-week range is between 38.27 and 47.04, which gives BME stock a 52-week price range ratio of 40.94%
Blackrock Health Sciences Trust currently has a PE ratio of 22.50, a price-to-book (PB) ratio of 4.50, a price-to-sale (PS) ratio of -9.29, a price to cashflow ratio of 15.90, a PEG ratio of 2.32, a ROA of 8.37%, a ROC of -% and a ROE of 27.60%. The company’s profit margin is 98.99%, its EBITDA margin is -%, and its revenue ttm is $-62 046 100.00 , which makes it $-4.60 revenue per share.
Of the last four earnings reports from Blackrock Health Sciences Trust, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Blackrock Health Sciences Trust’s next earnings report date is -.
The consensus rating of Wall Street analysts for Blackrock Health Sciences Trust is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Blackrock Health Sciences Trust stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Blackrock Health Sciences Trust has a dividend yield of 5.99% with a dividend per share of $2.56 and a payout ratio of 34.00%.
Blackrock Health Sciences Trust has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.93, ATR14 : 0.73, CCI20 : 126.78, Chaikin Money Flow : -0.23, MACD : -0.13, Money Flow Index : 68.23, ROC : 5.36, RSI : 57.69, STOCH (14,3) : 92.93, STOCH RSI : 0.95, UO : 58.83, Williams %R : -7.07), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Blackrock Health Sciences Trust in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
CEO: John M. Perlowski
Telephone: +1 800 882-0052
Address: 100 Bellevue Parkway, Wilmington 19809, DE, US
Number of employees: 0
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.